Evidence map›Paper›PMID 41735483›Full record

ArticleLeukemia2026

Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.

Nicolas Lecornec, Florence Rabian, Marie-Emilie Dourthe, Florian Chevillon, Karima Yakouben, Delphine Chaillou, Sophie Caillat-Zucman, Alexis Cuffel, Emmanuelle Lesprit, Anne Arnould and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Nicolas LecornecDepartment of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.ORCID 0000-0001-8073-4570
Florence RabianAdolescents and Young Adults Unit, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.ORCID 0000-0002-9695-193X
Marie-Emilie DourtheDepartment of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
Florian ChevillonAdolescents and Young Adults Unit, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
Karima YakoubenDepartment of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
Delphine ChaillouDepartment of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
Sophie Caillat-ZucmanLaboratory of Immunology, Hôpital Universitaire Saint Louis, AP-HP and INSERM UMR1149, Université́ Paris Cité, Paris, France.
Alexis CuffelLaboratory of Immunology, Hôpital Universitaire Saint Louis, AP-HP and INSERM UMR1149, Université́ Paris Cité, Paris, France.
Emmanuelle LespritEtablissement Français du Sang, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.
Anne ArnouldEtablissement Français du Sang, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.
Jérôme NaudinPediatric Intensive Care Unit, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.
Julie Roupret-SerzecDepartment of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
Nathalie ParquetTherapeutic Apheresis Unit, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
Anne BrignierTherapeutic Apheresis Unit, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
Valérie Guérin-El KhouroujLaboratory of Immunology, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.
Elodie LaineyLaboratory of Hematology, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.
Aurélie Caye-EudeDepartment of Genetics, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.ORCID 0000-0001-5996-3037
Chloé ArfeuilleDepartment of Genetics, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.
Emmanuelle ClappierLaboratory of Hematology, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
Rathana KimLaboratory of Hematology, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.ORCID 0000-0002-9987-7237
Stéphanie MathisLaboratory of Hematology, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
Marie-Laure ChaixLaboratory of Virology, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
Elie AzoulayIntensive Care Unit, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
Jean-Hugues DalleDepartment of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.ORCID 0000-0002-8406-0793
Isabelle MadelainePharmacy Department, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
Jérôme LargheroUnité́ de Thérapie Cellulaire et Centre MEARY de Thérapie Cellulaire et Génique, AP-HP and Université Paris Cité, Hôpital Saint- Louis, U1342 et CICBT, INSERM, Paris, France.
André Baruchel *Department of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.ORCID 0000-0003-0120-6089
Nicolas Boissel *Adolescents and Young Adults Unit, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France. nicolas.boissel@aphp.fr.ORCID 0000-0003-2091-7927

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tisagenlecleucel (tisa-cel), an autologous anti-CD19 CAR T-cell therapy, has significantly improved outcomes in pediatric, adolescents and young adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL). However, 30-50% experience early failure or relapse. We retrospectively analyzed 52 cases of early failures (n = 13) or relapses (n = 39), evaluating post-tisa-cel outcomes and prognostic factors. CD19 antigen loss was the only factor associated with a lower complete remission rate after salvage therapy (OR = 0.16, 95%CI [0.03-0.90], p = 0.04). Median overall survival (OS) was 14.5 months, with a 2-year OS of 37.4% (95%CI [24.4-50.4]), similar between early failure (38.5%) and relapse (37.0%) groups (p = 0.78). Patients with measurable residual disease only at salvage initiation had significantly improved 2-year OS (61.9%, (95%CI [38.1-78.8])) compared to those with overt disease (20.7%, (95%CI [8.4-36.7], p = 0.008)). Factors associated with inferior OS included high pre-infusion tumor burden (HR = 3.57, p < 0.01), and prior inotuzumab ozogamicin exposure (HR = 3.81, p < 0.01). Although salvage therapies and hematopoietic stem cell transplantation benefit some patients, 5 of 18 transplanted patients died from treatment-related toxicity, underscoring the significant associated risks. These findings highlight the poor prognosis of tisa-cel failures and the urgent need for novel strategies.

Indexed as

Immunotherapy, AdoptiveNeoplasm Recurrence, LocalPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellAdolescentAdultAntigens, CD19ChildChild, PreschoolFemaleFollow-Up StudiesHumansMalePrognosisRetrospective StudiesSalvage TherapyAntigens, CD19Receptors, Antigen, T-Celltisagenlecleucel

Identifiers

PMID41735483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.